Injectable flowable composition comprising buprenorphine

摘要

The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

主权项

1. An injectable flowable composition comprising: 8 wt % to about 30 wt % of buprenorphine or a pharmaceutically acceptable salt thereof; about 5 wt % to about 70 wt % of a poly(DL-lactide-co-glycolide) copolymer; and about 10 wt % to about 70 wt % of N-methyl-2-pyrrolidone; wherein the composition is transformed in situ into an implant by contact with water, body fluid or other aqueous medium.